Arylpiperazine derivatives and methods of utilizing same

ABSTRACT

The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/018,174, filed Feb. 8, 2016; which is a continuation of U.S.application Ser. No. 14/630,458, filed Feb. 24, 2015, now U.S. Pat. No.9,255,076; which is a continuation of U.S. application Ser. No.14/489,331, filed Sep. 17, 2014, now U.S. Pat. No. 8,980,883; which is adivisional application of U.S. application Ser. No. 13/914,424, filedJun. 10, 2013, now U.S. Pat. No. 8,859,552; which is a divisionalapplication of U.S. application Ser. No. 13/465,549, filed May 7, 2012,now U.S. Pat. No. 8,461,154; which is a divisional application of U.S.application Ser. No. 12/714,406, filed Feb. 26, 2010, now U.S. Pat. No.8,188,076; which claims the benefit of U.S. Provisional Application No.61/155,791, filed Feb. 26, 2009; the contents of the above applicationsare incorporated by reference in their entireties.

FIELD OF THE INVENTION

The present invention relates to compositions of arylpiperazinederivatives, synthesis of arylpiperazine derivatives, and methods ofutilizing arylpiperazine derivatives. The present invention moreparticularly relates to synthesis, compositions and methods of utilizingarylpiperazine based compounds which are useful for the pharmacologicaltreatment of schizophrenia and related psychoses such as acute manic,bipolar disorder, autistic disorder and depression.

BACKGROUND OF THE INVENTION

Medications used to treat psychotic disorders are called antipsychotics.Typical antipsychotics (sometimes referred to as conventionalantipsychotics) are class of first generation antipsychotic drugs andused to treat psychosis including schizophrenia. The typicalantipsychotics include chlorpromazine (THORAZINE®), fluphenazine(PROLIXIN®), haloperidol (HALDOL®), thiothixene (NAVANE®),trifluoroperazine (STELAZINE®), perphenazine (TRILAFON®), andthioridazine (MELLARIL®). The second generation antipsychoticsintroduced in the 1990's are called atypical antipsychotics. Compared tothe first generation antipsychotics, the atypical antipsychotics appearto be equally effective in reducing the positive symptoms likehallucinations and delusions but may be better than the typicalantipsychotics at relieving the negative symptoms of schizophrenia suchas apathy, withdrawal, emotional depression and the like. The atypicalantipsychotics currently in clinical use include Aripiprazole(ABILIFY®), clozapine (CLOZARIL®), risperidone (RISPERDAL®), olanzapine(ZYPREXA®), quetiapine (SEROQUEL®), and ziprasidone (GEODON®).

Atypical antipsychotics have diminished propensity to causeextrapyramidal symptoms (EPS) and tardive dyskinesia (TD) than typicalantipsychotics. Additional benefits associated with the atypicalantipsychotics include better treatment of negative symptoms, bettercompliance, possible benefits for cognitive impairments, and lower ratesof relapse. Within the class of atypical antipsychotics, however,differences exist both in efficacy and side effects. Clozapine does notcause EPS, and is clearly more effective than all other antipsychoticsused in humans to date. It is however a life-altering drug, because ofits side effects and need for continual medical monitoring, in somecountries, for agranulocytosis. This has markedly limited its use. Theother atypical antipsychotics with the greatest amount of efficacy dataare risperidone and olanzapine. These drugs are the most commonly usedfirst-line antipsychotics today. This is warranted because they are moreclinically effective than conventional drugs and much easier to use thanclozapine. However, both risperidone and olanzapine are limited by sideeffects. Risperidone causes prolactin elevations, weight gain anddose-dependant EPS. Olanzapine use is associated with much more weightgain in addition to lipid and glucose abnormalities. Qetiapine andZiprasidone may be safer alternatives to risperidone and olanzapine butthese drugs do not appear to be as clinically effective as the otheratypical antipsychotics. Aripiprazole is one of a new generation ofatypical antipsychotic drugs approved by the FDA for the treatment ofschizophrenia in November 2002 (Satyanarayana, C. et al. WO 2006/030446;Tsujimori, H. et al. WO 2004/063162; Salama, P. et al. WO 2004/099152;Wikstorm, H. et al. WO 2003/064393). It was approved for the treatmentof acute mania and mixed episode associated with bipolar disorder inMarch 2005. Aripiprazole does not differ greatly from other atypicalantipsychotics with respect to treatment response, efficacy andtolerability.

Atypical antipsychotics are increasingly being used in children andadolescents for a variety of psychiatric conditions. Conditions forwhich atypical antipsychotics are prescribed include bipolar disorder,psychotic depression, schizophrenia, pervasive developmental disorders,attention-deficit/hyperactivity disorder (ADHD), oppositional defiantdisorder (ODD), and conduct disorder. They are also used symptomaticallyto treat rage, insomnia, and anorexia. Younger patients appear to be ata higher risk of adverse effects associated with the treatment ofatypical antipsychotics especially weight gain and drug induced diabetesmellitus.

In general, atypical antipsychotics share many of the side effects oftypical antipsychotics, including sedation, akathisia, weight gain,extrapyramidal symptoms (EPS), neuromalignant syndrome, and tardivedyskinesia; longer experience with them have shown that new risks needto be considered, such as metabolic syndromes and QTc prolongation. QTcprolongation is known to have potential liability to produce fatalcardiac arrhythmias of Torsades de Pointes (TdP). Drug induced adversemetabolic effects such as weight gain, lipid abnormalities, and diabetesmellitus have been identified as a major risk factor for various medicaldisorders that might be responsible for some of the increased morbidityand mortality rates in psychotic patients treated with atypicalantipsychotics.

Off-target pharmacology and drug to drug interactions are mainlyresponsible for most of the adverse side effects associated with theatypical antipsychotics. All the atypical antipsychotic drugs currentlybeing used for the treatment of schizophrenia and related psychoticdisorders have poor therapeutic target selectivity. For example, one ofthe most widely prescribed atypical antipsychotic drugs, Olanzapine andthe most effective atypical antipsychotic drug, clozapine are reportedto have significant activities against more than 12 receptors such asdopamine (D₁, D₂, D₃ and D₄), serotonin (5-HT_(2A), 5-HT_(2C), 5-HT₆,and 5-HT₇), adrenergic (alpha 1 and alpha 2), histamine (H₁), muscarinic(M₁), Dopamine transporter (DAT) and norepinephrine transporter (NET)receptors (Miyamoto et al., Molecular Psychiatry, 2005, 10, 79).Similarly, the other FDA approved atypical antipsychotics such asrisperidone and aripiprazole are also reported to have significantactivities against more than nine of the receptors mentioned above. Thecurrent research suggests that compounds exhibiting activity againstdopamine (D₂) and serotonin (5-HT_(1A) and 5-HT_(2A)) receptors may havethe intended antipsychotic effect (Snyder, S. H., Nature 2008, 452,38-39; Di Pietro, N. C., Seamans, J. K., Pharmacopsychitry 2007, 40(S1),S27-S33; Stark, A. D. et al., Psychopharmacology 2007, 190, 373-382)while compounds exhibiting activity against other receptors likeserotonin, 5HT_(2C), histamine (H₁), and adrenergic (alpha 1) may causeadverse side effects such as cardiac arrhythmias.

Although, the atypical antipsychotics (aripiprazole, clozapine,risperidone, olanzapine, quetiapine, and ziprasidone) currently inclinical use represent significant advances in treatment of people withschizophrenia, there is a need for new psychotropic drugs with improvedsafety profiles.

Therefore, development of a novel antipsychotic that has improvedtherapeutic target selectivity than the currently available therapieswould provide effective and safer medicines for the treatment ofschizophrenia and related psychotic disorders.

SUMMARY OF THE INVENTION

The present invention provides compounds, synthesis of the compounds,compositions and methods of using the compounds for treatingschizophrenia and related psychoses such as acute manic, bipolardisorder, autistic disorder and depression, where the compounds arearylpiperazine derivatives. The present invention provides methods forsynthesizing such arylpiperazine compounds. The present invention alsoprovides methods for using arylpiperazine based atypical antipsychotics,and composition of arylpiperazine based atypical antipsychotics fortreating schizophrenia and related psychoses such as acute manic,bipolar disorder, autistic disorder and depression.

The compounds of the subject invention provide next generation novelantipsychotics that are particularly effective and safer for thetreatment of schizophrenia. They are advantageous because of theirhighly desirable pharmacological, metabolic, and pharmacokineticsprofiles. The compounds of the invention are designed:

-   -   1) to exhibit affinity for dopamine 2 (D₂) receptor;    -   2) to exhibit affinity for serotonin 1A (5-HT_(1A)) receptor;    -   3) to exhibit affinity for serotonin 2A (5-HT_(2A)) receptors    -   4) to form therapeutically inactive or least active        metabolite(s).

In one aspect, the present invention provides arylpiperazine derivativescomprising compounds of Formula (1):

wherein:

-   A is —(CH₂)_(n)—, —O—(CH₂)_(n)—, —S—(CH₂)—, —S(O)(O)—(CH₂)_(n)—,    —NH—(CH₂)—, —CH₂—O—(CH₂)_(n)—, —(CH₂)_(n)—O—CH₂—CH₂—,    —CH₂—S—(CH₂)_(n)—, —(CH₂)_(n)—S—CH₂—CH₂—, —CH₂—S(O)(O)—(CH₂)_(n)—,    —(CH₂)_(n)—S(O)(O)—CH₂—CH₂—, —O—C(O)—(CH₂)_(n)—, —S—C(O)—(CH₂)_(n)—,    —NH—C(O)—(CH₂)_(n)—, —CH₂—C(O)—O—(CH₂)_(n)—,    —CH₂—C(O)—NH—(CH₂)_(n)—, —CH₂—C(O)—S—(CH₂)_(n)—,    —(CH₂)_(n)—C(O)—O—CH₂—CH₂—, —(CH₂)_(n)—C(O)—NH—CH₂—CH₂—,    —(CH₂)_(n)—C(O)—S—CH₂—CH₂—, —CH₂—O—C(O)—(CH₂)_(n)—,    —CH₂—NH—C(O)—(CH₂)_(n)—, —CH₂—S—C(O)—(CH₂)_(n)—,    —(CH₂)_(n)—O—C(O)—CH₂—CH₂—, (CH₂)_(n)—NH—C(O)—CH₂—CH₂—, or    (CH₂)_(n)—S—C(O)—CH₂—CH₂—, wherein n is an integer from 1 to 7;-   B is O, S, S(O)(O), or NR⁵; and-   each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is independently    hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,    arylalkyl, substituted arylalkyl, cycloalkyl, substituted    cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,    heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted    heteroarylalkyl, acylalkyloxycarbonyl, acyloxyalkyloxycarbonyl,    acylalkyloxycarbonylamino, acyloxyalkyloxycarbonylamino, alkoxy,    alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonyllalkylamino,    alkylasulfinyl, alkylsulfonyl, alkylthio, amino, alkylamino,    arylalkylamino, dialkkylamino, arylalkoxy, arylalkoxycarbonylalkoxy,    arylalkoxycarbonylalkylamino, aryloxycarbonyl,    arylloxycarbonylalkoxy, aryloxycarbonylalkylamino, carboxy,    carbamoyl, carbamate, carbonate, cyano, halo, heteroaryloxycarbonyl,    hydroxy, phosphate, phosphonate, sulfate, sulfonate, or sulfonamide,    wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ and A may optionally be    substituted with isotopes that include, but not limited to ²H    (deuterium), ³H (tritium), ¹³C, ³⁶Cl, ¹⁸F, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P,    and ³⁵S;-   or a pharmaceutically acceptable salt, racemate or diastereomeric    mixtures thereof.

In one aspect of the invention, pharmaceutical compositions are providedcomprising the compounds of the present disclosure.

In one aspect of the invention, methods of treating one of psychoses,schizophrenia, acute mania, bipolar disorder, autistic disorder ordepression are described, comprising administering to a patient in needthereof the compounds of the present disclosure.

In one aspect of the invention, compounds of the present disclosure areused to treat psychoses, schizophrenia, acute mania, bipolar disorder,autistic disorder or depression.

In one aspect of the invention, compounds of present disclosure are usedin the manufacture of a medicament for use in the treatment ofpsychoses, schizophrenia, acute mania, bipolar disorder, autisticdisorder or depression treat psychoses, schizophrenia, acute mania,bipolar disorder, autistic disorder or depression.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to synthesis, compositions and methods ofusing arylpiperazine derivatives which are useful for treatingschizophrenia and related psychoses such as acute manic, bipolardisorder, autistic disorder and depression. The present inventionprovides compounds, compositions and methods for pharmacologicaltreatment of schizophrenia and related psychoses such as acute manic,bipolar disorder, autistic disorder, and depression.

Definitions

Unless otherwise stated, the following terms used in this application,including the specification and claims, have the definitions givenbelow. Any terms not directly defined herein shall be understood to havethe meanings commonly associated with them as understood within the artof the present disclosure.

It must be noted that, as used in the specification and the appendedclaims, the singular forms “a,” “an” and “the” include plural referentsunless the context clearly dictates otherwise.

Definition of standard chemistry terms may be found in reference works,including Carey and Sundberg (1992) “Advanced Organic Chemistry 3^(rd)Ed.” Vols. A and B, Plenum Press, New York. The practice of the presentinvention will employ, unless otherwise indicated, conventional methodsof mass spectroscopy, protein chemistry, biochemistry, recombinant DNAtechniques and pharmacology, within the skill of the art. Thecompositions and formulations described herein can be practicedemploying the pharmaceutically acceptable excipients and salts availablein Remington's Pharmaceutical Sciences, 18^(th) Edition (Easton, Pa.:Mack Publishing Company, 1990).

“Compounds of the invention” refers to compounds encompassed bystructural Formula (1) as disclosed herein. The compounds of theinvention can be identified either by their chemical structure and/orchemical name. When the chemical structure and chemical name conflict,the chemical structures is determinative of the identity of thecompound. The compounds of the invention may contain one or more chiralcenters and/or double bonds and therefore, may exist as stereoisomers,such as double-bond isomers (i.e., geometric isomers), enantiomers ordiastereoisomers. Accordingly, the chemical structures depicted hereinencompass all possible enantiomers and stereoisomers of the illustratedcompounds including the stereoisomerically pure form (e.g.,geometrically pure, enantiomerically pure or diastereomerically pure)and enantiomeric and stereoisomeric mixtures. Enantiomeric andstereoisomeric mixtures can be resolved into their component enantiomersor stereoisomers using separation techniques or chiral synthesistechniques well known to the skilled artisan. The compounds of theinvention may also exist in several tautomeric forms including the enolform, the keto form and mixtures thereof. Accordingly, the chemicalstructures depicted herein encompass all possible tautomeric forms ofthe illustrated compounds. The compounds of the invention also includeisotopically labeled compounds where one or more atoms have an atomicmass different from the atomic mass of conventionally found in nature.Examples of isotopes that may be incorporated into the compounds of theinvention include, but are not limited to ²H, ³H, ¹³C, ¹⁵N, ¹⁸O, ¹⁷O,³¹P, ³²P, ³⁵S, ¹⁸F and ³⁶Cl. Further, it should be understood, whenpartial structures of the compounds of the invention are illustrated,that brackets of dashes indicate the point of attachment of the partialstructure to the rest of the molecule.

“Composition of the invention” refers to at least one compound of theinvention and a pharmaceutically acceptable vehicle, with which thecompound is administered to a patient. When administered to a patient,the compounds of the invention are administered is isolated form, whichmeans separated from a synthetic organic reaction mixture.

“Alkyl” refers to a saturated or unsaturated, branched, straight-chainor cyclic monovalent hydrocarbon radical derived by the removal of onehydrogen atom from a single carbon atom of a parent alkane, alkene oralkyne. Typical alkyl groups include, but are not limited to methyl;ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl,propan-2yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl,prop-2-en-1-yl (allyl), cycloprop-1-en-1yl, cycloprop-2-en-yl,prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls such as butan-1-yl,butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl,but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl,but-2-en-2-yl, buta-1, 3-dien-1-yl, buta-1, 3-dien-2-yl,cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl,but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like.

The term “alkyl” specifically intended to include radicals having anydegree or level of saturation, i.e., groups having exclusively singlecarbon-carbon bonds, groups having one or more double carbon-carbonbonds, groups having one or more triple carbon-carbon bonds and groupshaving mixtures of single, double and triple carbon-carbon bonds. Wherea specific level of saturation is intended, the expressions “alkanyl,”“alkenyl,” and “alkynyl,” are used. Preferably, an alkyl group comprisesfrom 1-20 carbon atoms, more preferably, from 1 to 10 carbon atoms.

“Alkanyl” refers to a saturated branched, straight-chain or cyclic alkylradical derived by the removal of one hydrogen atom from a single carbonatom of a parent alkane. Typical alkanyl groups include but are notlimited to, methanyl; ethanyl; propanyls such as propan-1-yl,propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such asbutan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl (isobutyl),2-methyl-propan-2-yl (t-butyl), cyclobutan-1-yl, etc.; and the like.

“Alkenyl” refers to an unsaturated branched, straight-chain or cyclicalkyl radical having at least one carbon-carbon double bond derived bythe removal of one hydrogen atom from a single carbon atom of a parentalkene. The group may be in either the cis or trans conformation aboutthe double bond(s). Typical alkenyl groups include, but are not limitedto, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl,prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl,cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl,2-methy-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl,buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl,cyclobut-1-en-3-yl, cyclobuta-1,3-dien 1-yl, etc.; and the like.

“Alkynyl” refers to an unsaturated branched, straight-chain or cyclicalkyl radical having at least one carbon-carbon triple bond derived bythe removal of one hydrogen atom from a single carbon atom of a parentalkyne. Typical alkynyl groups include, but are not limited to, ethynyl;propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such asbut-1-yn-1-yl, but-1-yn3-yl, but-3-yn-1-yl, etc.; and the like.

“Acyl” refers to a radical —C(O)R, where R is hydrogen, alkyl,cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to formyl, acetyl, cyclohexylcarbonyl,cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

“Acyloxyalkyloxycarbonyl” refers to a radical —C(O)OCR′R″OC(O)R′″, whereR′, R″, and R′″ are each independently hydrogen, alkyl, cycloalkyl,cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but not limited to —C(O)OCH₂OC(O)CH₃, —C(O)OCH₂OC(O)CH₂CH₃,—C(O)OCH(CH₃)OC(O)CH₂CH₃, —C(O)OCH(CH₃)OC(O)C₆H₅ and the like.

“Acylalkyloxycarbonyl” refers to a radical —C(O)OCR′R″C(O)R′″, where R′,R″, and R′″ are each independently hydrogen, alkyl, cycloalkyl,cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but not limited to —C(O)OCH₂C(O)CH₃, —C(O)OCH₂C(O)CH₂CH₃,—C(O)OCH(CH₃)C(O)CH₂CH₃, —C(O)OCH(CH₃)C(O)C₆H₅ and the like.

“Acyloxyalkyloxycarbonylamino” refers to a radical—NRC(O)OCR′R″OC(O)R′″, where R, R′, R″, and R′″ are each independentlyhydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl,heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may beoptionally substituted by one or more substituents as defined herein.Representative examples include, but not limited to —NHC(O)OCH₂OC(O)CH₃,—NHC(O)OCH₂OC(O)CH₂CH₃, —NHC(O)OCH(CH₃)OC(O)CH₂CH₃,—NHC(O)OCH(CH₃)OC(O)C₆H₅ and the like.

“Acylalkyloxycarbonylamino” refers to a radical —NRC(O)OCR′R″C(O)R′″,where R, R′, R″, and R′″ are each independently hydrogen, alkyl,cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but not limited to —NHC(O)OCH₂C(O)CH₃, —NHC(O)OCH₂C(O)CH₂CH₃,—NHC(O)OCH(CH₃)C(O)CH₂CH₃, —NHC(O)OCH(CH₃)C(O)C₆H and the like.

“Acylamino” refers to “amide” as defined herein.

“Alkylamino” means a radical —NHR where R represents an alkyl, orcycloalkyl group as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to, methylamino, ethylamino,1-methylethylamino, cyclohexylamino and the like.

“Alkoxy” refers to a radical —OR where R represents an alkyl, orcycloalkyl group as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to methoxy, ethoxy, propoxy, butoxy,cyclohexyloxy and the like.

“Alkoxycarbonyl” refers to a radical —C(O)-alkoxy where alkoxy is asdefined herein.

“Alkoxycarbonylalkoxy” refers to a radical —OCR′R″ C(O)-alkoxy wherealkoxy is as defined herein. Similarly, where R′ and R″ are eachindependently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to—OCH₂C(O)OCH₃, —OCH₂C(O)OCH₂CH₃, —OCH(CH₃)C(O)OCH₂CH₃,—OCH(C₆H₅)C(O)OCH₂CH₃, —OCH(CH₂C₆H₅)C(O)OCH₂CH₃,—OC(CH₃)(CH₃)C(O)OCH₂CH₃, and the like.

“Alkoxycarbonylalkylamino” refers to a radical —NRCR′R″C(O)-alkoxy wherealkoxy is as defined herein. Similarly, where R, R′, R′ and R″ are eachindependently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to—NHCH₂C(O)OCH₃, —N(CH₃)CH₂C(O)OCH₂CH₃, —NHCH(CH₃)C(O)OCH₂CH₃,—NHCH(C₆H₅)C(O)OCH₂CH₃, —NHCH(CH₂C₆H₅)C(O)OCH₂CH₃,—NHC(CH₃)(CH₃)C(O)OCH₂CH₃, and the like.

“Alkylsulfonyl” refers to a radical —S(O)₂R where R is an alkyl, orcycloalkyl group as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to, methylsulfonyl, ethylsulfonyl,propylsulfonyl, butylsulfonyl, and the like.

“Alkylsulfinyl” refers to a radical —S(O)R where R is an alkyl, orcycloalkyl group as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to, methylsulfinyl, ethylsulfinyl,propylsulfinyl, butylsulfinyl, and the like.

“Alkylthio” refers to a radical —SR where R is an alkyl or cycloalkylgroup as defined herein that may be optionally substituted by one ormore substituents as defined herein. Representative examples include,but are not limited to methylthio, ethylthio, propylthio, butylthio, andthe like.

“Amide” or “acylamino” refers to a radical —NR′C(O)R″, where R′ and R″are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl,aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as definedherein that may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to,formylamino acetylamino, cyclohexylcarbonylamino,cyclohexylmethylcarbonyl-amino, benzoylamino, benzylcarbonylamino andthe like.

“Amino” refers to the radical —NH₂.

“Aryl” refers to a monovalent aromatic hydrocarbon radical derived bythe removal of one hydrogen atom from a single carbon atom of a parentaromatic ring system. Typical aryl groups include, but are not limitedto, groups derived from aceanthrylene, acenaphthylene,acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene,fluoranthene, fluorine, hexacene, hexaphene, hexalene, as-indacene,s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene,ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene,phenalene, phenanthrene, picene, pleidene, pyrene, pyranthrene,rubicene, triphenylene, trinaphthalene, and the like. Preferable, anaryl group comprises from 6 to 20 carbon atoms, more preferably, between6 to 12 carbon atoms.

“Arylalkyl” refers to an acyclic alkyl in which one of the hydrogenatoms bonded to a carbon atom, typically a terminal or sp³ carbon atom,is replaced with an aryl group. Typically arylalkyl groups include, butnot limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl,naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl,naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specificalkyl moieties are intended, the nomenclature arylalkany, arylalkenyland/or arylalkynyl is used. Preferably, an arylalkyl group is(C₆-C₃₀)arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of thearylalkyl group is (C₁-C₁₀) and the aryl moiety is (C₆-C₂₀), morepreferably, an arylalkyl group is (C₆-C₂₀) arylalkyl, e.g., the alkanyl,alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₅) and the arylmoiety is (C₆-C₁₂).

“Arylalkoxy” refers to an —O-arylalkyl radical where arylalkyl is asdefined herein that may be optionally substituted by one or moresubstituents as defined herein.

“Arylalkoxycarbonylalkoxy” refers to a radical —OCR′R″C(O)-arylalkoxywhere arylalkoxy is as defined herein. Similarly, where R′ and R″ areeach independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to—OCH₂C(O)OCH₂C₆H₅, —OCH(CH₃)C(O)O CH₂C₆H₅, —OCH(C₆H₅)C(O)O CH₂C₆H₅,—OCH(CH₂C₆H₅)C(O)O CH₂C₆H₅, —OC(CH₃)(CH₃)C(O)O CH₂C₆H₅, and the like.

“Arylalkoxycarbonylalkylamino” refers to a radical—NRCR′R″C(O)-arylalkoxy where arylalkoxy is as defined herein.Similarly, where R, R′, R′ and R″ are each independently hydrogen,alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl,heteroaryl, heteroarylalkyl, as defined herein that may be optionallysubstituted by one or more substituents as defined herein.Representative examples include, but are not limited to—NHCH₂C(O)OCH₂C₆H₅, —N(CH₃)CH₂C(O)OCH₂C₆H₅, —NHCH(CH₃)C(O)OCH₂C₆H₅,—NHCH(C₆H₅)C(O)OCH₂C₆H₅, —NHCH(CH₂C₆H₅)C(O)OCH₂C₆H₅,—NHC(CH₃)(CH₃)C(O)OCH₂C₆H₅, and the like.

“Aryloxycarbonyl” refers to radical —C(O)—O-aryl where aryl is definedherein that may be optionally substituted by one or more substituents asdefined herein.

“Aryloxycarbonylalkoxy” refers to a radical —OCR′R″C(O)-aryloxy wherearyloxy is as defined herein. Similarly, where R′ and R″ are eachindependently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to—OCH₂C(O)OC₆H₅, —OCH(CH₃)C(O)OC₆H₅, —OCH(C₆H₅)C(O)OC₆H₅,—OCH(CH₂C₆H₅)C(O)OC₆H₅, —OC(CH₃)(CH₃)C(O)OC₆H₅, and the like.

“Aryloxycarbonylalkylamino” refers to a radical —NRCR′R″C(O)-aryloxywhere aryloxy is as defined herein. Similarly, where R, R′, R′ and R″are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl,aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as definedherein that may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to—NHCH₂C(O)OC₆H₅, —N(CH₃)CH₂C(O)OC₆H₅, —NHCH(CH₃)C(O)OC₆H₅,—NHCH(C₆H₅)C(O)OC₆H₅, —NHCH(CH₂C₆H₅)C(O)OC₆H₅, —NHC(CH₃)(CH₃)C(O)OC₆H₅,and the like.

“Carbamoyl” refers to the radical —C(O)NRR where each R group isindependently, hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein.

“Carbamate” refers to a radical —NR′C(O)OR″, where R′ and R″ are eachindependently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to,methylcarbamate (—NHC(O)OCH₃), ethylcarbamate (—NHC(O)OCH₂CH₃),benzylcarbamate (—NHC(O)OCH₂C₆H₅), and the like.

“Carbonate” refers to a radical —OC(O)OR, where R is alkyl, cycloalkyl,cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein. Representative examplesinclude, but are not limited to, methyl carbonate (—C(O)OCH₃),cyclohexyl carbonate (—C(O)OC₆H₁₁), phenyl carbonate (—C(O)OC₆H₅),benzyl carbonate (—C(O)OCH₂C₆H₅), and the like.

“Carboxy” means the radical —C(O)OH.

“Cyano” means the radical —CN.

“Cycloalkyl” refers to a substituted or unsubstituted cylic alkylradical. Where a specific level of saturation is intended, thenomenclature “cycloalkanyl” or “cycloalkenyl” is used. Typicalcycloalkyl groups include, but are not limited to, groups derived fromcyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. In apreferred embodiment, the cycloalkyl group is (C₃-C₁₀) cycloalkyl, morepreferably (C₃-C₇) cycloalkyl.

“Cycloheteroalkyl” refers to a saturated or unsaturated cyclic alkylradical in which one or more carbon atoms (and any associated hydrogenatoms) are independently replaced with the same or different heteroatom.Typical heteroatoms to replace the carbon atom(s) include, but are notlimited to, N, P, O, S, Si, etc. Where a specific level of saturation isintended, the nomenclature “cycloheteroalkanyl” or “cycloheteroalkenyl”is used. Typical cycloheteroalkyl groups include, but are not limitedto, groups derived from epoxides, imidazolidine, morpholine, piperazine,piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like.

“Cycloheteroalkoxycarbonyl” refers to a radical —C(O)—OR where R iscycloheteroalkyl as defined herein that may be optionally substituted byone or more substituents as defined herein.

“Dialkylamino” means a radical —NRR′ where R and R′ independentlyrepresent an alkyl or cycloalkyl group as defined herein that may beoptionally substituted by one or more substituents as defined herein.Representative examples include, but are not limited to dimethylamino,methylethylamino, di-(1-methylethyl)amino, (cyclohexyl)(methyl)amino,(cyclohexyl)(ethyl)amino, (cyclohexyl)(propyl)amino, and the like.

“Derived from a drug” refers to a fragment that is structurally relatedto such a drug. The structure of the fragment is identical to the drugexcept where a hydrogen atom attached to a heteroatom (N or O) has beenreplaced with a covalent bond to another group (typically, a promoiety).Note that when a drug is a salt form of a carboxylic, phosphonic orphosphoric acid, the corresponding structural fragment derived from sucha drug is considered to be derived from the protonated acid form.

“Drug” refers to a compound that exhibits therapeutic and/orprophylactic and/or diagnostic utility when administered in effectiveamounts to a patient or a mammal.

“Ester” refers to a radical —C(O)OR, where R is alkyl, substitutedalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substitutedcycloheteroalkyl, aryl, substituted aryl, arylalkyl, substitutedarylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substitutedheteroaryl, heteroarylalkyl, substituted heteroarylalkyl as definedherein that may be optionally substituted by one or more substituents asdefined herein. Representative examples include, but are not limited to,methyl ester (—C(O)OCH₃), cyclohexyl ester (—C(O)OC₆H₁₁), phenyl ester(—C(O)OC₆H₅), benzyl ester (—C(O)OCH₂C₆H₅), and the like.

“Ether” refers to a radical —OR, where R is alkyl, cycloalkyl,cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein.

“Halo” means fluoro, chloro, bromo, or iodo.

“Heteroalkoxy” means an —O-heteroalkyl radical where heteroalkyl is asdefined herein that may be optionally substituted by one or moresubstituents as defined herein.

“Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkynyl” refer toalkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which oneor more of the carbon atoms (and any associated hydrogen atoms) are eachindependently replaced with the same or different heteroatomic groups.Typical heteroatomic groups include, but are not limited to —O—, —S—,—O—O—, —S—S—, —OS—, —NR′—, ═N—N═, —N═N—, —N═N—NR′—, —PH—, —P(O)₂—,—O—P(O)₂—, —S(O—, —S(O)₂—, —SnH₂—, and the like, wherein R′ is hydrogen,alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl orsubstituted aryl that may be optionally substituted by one or moresubstituents as defined herein.

“Heteroaryl” refers to a monovalent heteroaromatic radical derived bythe removal of one hydrogen atom from a single atom of a parentheteroaromatic ring system. Typical heteroaryl groups include, but arenot limited to, groups derived from acridine, arsindole, carbazole,carboline, chromane, chromene, cinnoline, furan, imidazole, indazole,indole, indoline, indolizine, isobenzofuran, isochromene, isoindole,isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine,oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline,phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole,pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline,quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole,thiophene, triazole, xanthene, and the like. Preferably, the heteroarylgroup is between 5-20 membered heteroaryl, with 5-10 membered heteroarylbeing particularly preferred. Preferred heteroaryl groups are thosederived from thiophene, pyrrole, benzothiophene, benzofuran, indole,pyridine, quinoline, imidazole, oxazole and pyrazine.

“Heteroaryloxycarbonyl” refers to a radical —C(O)OR where R isheteroaryl as defined that may be optionally substituted by one or moresubstituents as defined herein.

“Heteroarylalkyl” refers to an acyclic alkyl radical in which one of thehydrogen atoms bonded to a carbon atom, typically a terminal or sp3carbon atom, is replaced with a heteroaryl group. Where specific alkylmoieties are intended, the nomenclature heteroarylalkanyl,heteroarylalkenyl and/or heteroarylalkynyl is used. Preferably, theheteroarylalkyl radical is a 6-30 carbon membered heteroarylalkyl, e.g.,the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-10membered and the heteroaryl moiety is a 5-20 membered heteroaryl, morepreferably, a 6-20 membered heteroarylalkyl, e.g., the alkanyl, alkenylor alkynyl moiety of the heteroarylalkyl is 1-8 membered and theheteroaryl moiety is a 5-12 membered heteroaryl.

“Hydroxy” means the radical —OH.

“Oxo” means the divalent radical ═O.

As used herein, the term “patient” encompasses mammals and non-mammals.Examples of mammals include, but are not limited to, any member of theMammalian class: humans, non-human primates such as chimpanzees, andother apes and monkey species; farm animals such as cattle, horses,sheep, goats, swine; domestic animals such as rabbits, dogs, and cats;laboratory animals including rodents, such as rats, mice and guineapigs, and the like. Examples of non-mammals include, but are not limitedto, birds, fish and the like. The term does not denote a particular ageor gender.

“Pharmaceutically acceptable” means approved or approvable by aregulatory agency of the Federal or state government or listed in theU.S. Pharmacopoeia or other generally recognized pharmacopoeia for usein animals, and more particularly in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of theinvention, which is pharmaceutically acceptable and possesses thedesired pharmacological activity of the parent compound. Such saltsinclude: (1) acid addition salts, formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like; or formed with organic acids such asacetic acid, propionic acid, hexanoic acid, cyclopentane propionic acid,glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid,malic acid, maleic acid, fumaric acid, tartaric acid, citric acid,benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelicacid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonicacid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid,4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,4-toluenesulfonic acid, camphorsulfonic acid,4-methylbicyclo[2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid,3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid,laurylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoicacid, salicylic acid, stearic acid, muconic acid, and the like; or (2)salts formed when an acidic proton present in the parent compound isreplaced by a metal ion, e.g., an alkali metal ion, an alkaline earthion, or an aluminum ion; or coordinates with an organic base such asethanolamine, diethanolamine, triethanolamine, N-methylglucamine and thelike.

“Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant,excipient or carrier with which a compound of the invention isadministered.

“Phosphate” refers to a radical —OP(O)(OR′)(OR″), where R′ and R″ areeach independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein.

“Phosphonate” refers to a radical —P(O)(OR′)(OR″), where R′ and R″ areeach independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein.

“Preventing” or “Prevention” refers to a reduction in risk of acquiringa disease or disorder (i.e., causing at least one of the clinicalsymptoms of the disease not to develop in a patient that may be exposedto or predisposed to the disease but does not yet experience or displaysymptoms of the disease).

“Protecting group” refers to a group of atoms that when attached to areactive group in a molecule masks, reduces or prevents that reactivity.Examples of protecting groups can be found in Green et al., “ProtectiveGroups in Organic Chemistry”, (Wiley, 2^(nd) ed. 1991) and Harrison etal., “Compendium of Synthetic Organic Methods”, vols. 1-8 (John Wileyand Sons, 1971-1996). Representative amino protecting groups include,but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl,benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl(“TMS”), 2-trimethylsilyl-ethanesulfonyl (“SES”), trityl and substitutedtrityl groups, allyloxycarbonyl, 9-fluorenylmethyloxy-carbonyl (“FMOC”),nitroveratryloxycarbonyl (“NVOC”) and the like. Representative hydroxylprotecting groups include, but are not limited to, those where thehydroxyl group is either acylated or alkylated such as benzyl, andtrialkylsilyl ethers and allyl ethers.

“Racemate” refers to an equimolar mixture of enantiomers of a chiralmolecule.

“Substituted” refers to a group in which one or more hydrogen atoms areeach independently replaced with the same or different substituents(s).Typical substituents include, but are not limited to, —X, —R⁵⁴, —O⁻, ═O,—OR⁵⁴, —SR⁵⁴, —S, ═S, —NR⁵⁴R⁵⁵, ═NR⁵⁴, —CX₃, —CF₃, —CN, —OCN, —SCN, —NO,—NO₂, ═N₂, —N₃, —S(O)₂O⁻, —S(O)₂OH, —S(O)₂OR⁵⁴, OS(O)₂O³¹, —OS(O)₂R⁵⁴,—P(O)(O—)₂, —P(O)(OR¹⁴)(O³¹), —OP(O)(OR⁵⁴)(OR⁵⁵), —C(O)R⁵⁴, —C(S)R⁵⁴,—C(O)OR⁵⁴, —C(O)NR⁵⁴R⁵⁵, —C(O)O⁻, —C(S)OR⁵⁴, —NR⁵⁶C(O)NR⁵⁴R⁵⁵,—NR⁵⁶C(S)NR⁵⁴R⁵⁵, —NR⁵⁷C(NR⁵⁶)NR⁵⁴R⁵⁵, and —C(NR⁵⁶NR⁵⁶)N⁵⁴R⁵⁵, whereeach X is independently a halogen; each R⁵⁴, R⁵⁵, R⁵⁶ and R⁵⁷ areindependently hydrogen, alkyl, substituted alkyl, aryl, substitutedaryl, arylalkyl, substituted arylalkyl, cycloalkyl, substitutedcycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl,substituted heteroalkyl, heteroaryl, substituted heteroaryl,heteroarylalkyl, substituted heteroarylalkyl, —NR⁵⁸R⁵⁹, —C(O)R⁵⁸ or—S(O)₂R⁵⁸ or optionally R⁵⁸ and R⁵⁹ together with the atom to which theyare both attached form a cycloheteroalkyl or substitutedcycloheteroalkyl ring; and R⁵⁸ and R⁵⁹ are independently hydrogen,alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substitutedarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl,substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl,heteroaryl, substituted heteroaryl, heteroarylalkyl, substitutedheteroarylalkyl.

“Sulfate” refers to a radical —OS(O)(O)OR, where R is hydrogen, alkyl,cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein.

“Sulfonamide” refers to a radical —S(O)(O)NR′R″, where R′ and R″ areindependently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl,arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined hereinthat may be optionally substituted by one or more substituents asdefined herein or optionally R′ and R″ together with the atom to whichthey are both attached form a cycloheteroalkyl or substitutedcycloheteroalkyl ring. Representative examples include but not limitedto azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl,4-(NR′″)-piperazinyl or imidazolyl group wherein said group may beoptionally substituted by one or more substituents as defined herein.R′″ hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl,heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may beoptionally substituted by one or more substituents as defined herein.

“Sulfonate” refers to a radical —S(O)(O)OR, where R is hydrogen, alkyl,cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein.

“Thio” means the radical —SH.

“Thioether” refers to a radical —SR, where R is alkyl, cycloalkyl,cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl,heteroarylalkyl, as defined herein that may be optionally substituted byone or more substituents as defined herein.

“Treating” or “Treatment” of any disease or disorder refers, in oneembodiment, to ameliorating the disease or disorder (i.e., arresting orreducing the development of the disease or at least one of the clinicalsymptoms thereof). In another embodiment “treating” or “treatment”refers to ameliorating at least one physical parameter, which may not bediscernible by the patient. In yet another embodiment, “treating” or“treatment” refers to inhibiting the disease or disorder, eitherphysically (e.g., stabilization of a discernible symptom),physiologically, (e.g., stabilization of a physical parameter), or both.In yet another embodiment, “treating” or “treatment” refers to delayingthe onset of the disease or disorder.

“Therapeutically effective amount” means the amount of a compound that,when administered to a patient for treating a disease, is sufficient toeffect such treatment for the disease. The “therapeutically effectiveamount” will vary depending on the compound, the disease and is severityand the age, weight, etc., of the patient to be treated, and can bedetermined by one of skill in the art without undue experimentation.

Reference now will be made in detail to preferred embodiments of theinvention. While the invention will be described in conjunction withpreferred embodiments, it will be understood that it is not intended tolimit the invention to those preferred embodiments. To the contrary, itis intended to cover alternatives, modifications, and equivalents as maybe included within the spirit and scope of the invention as defined bythe appended claims.

COMPOUNDS OF THE INVENTION

In one aspect of the present invention, compounds of Formula (1) aredescribed:

wherein:

-   A is —(CH₂)_(n)—, —O—(CH₂)_(n)—, —S—(CH₂)_(n)—, —S(O)(O)—(CH₂)_(n)—,    —NH—(CH₂)_(n)—, —CH₂—O—(CH₂)_(n)—, —(CH₂)_(n)—O—CH₂—CH₂—,    —CH₂—S—(CH₂)_(n)—, —(CH₂)—S—CH₂—CH₂—, —CH₂—S(O)(O)—(CH₂)_(n)—,    —(CH₂)_(n)—S(O)(O)—CH₂—CH₂—, —O—C(O)—(CH₂)_(n)—, —S—C(O)—(CH₂)_(n)—,    —NH—C(O)—(CH₂)_(n)—, —CH₂—C(O)—O—(CH₂)_(n)—,    —CH₂—C(O)—NH—(CH₂)_(n)—, —CH₂—C(O)—S—(CH₂)_(n)—,    —(CH₂)—C(O)—O—CH₂—CH₂—, —(CH₂)_(n)—C(O)—NH—CH₂—CH₂—,    —(CH₂)_(n)—C(O)—S—CH₂—CH₂—, —CH₂—O—C(O)—(CH₂)_(n)—,    —CH₂—NH—C(O)—(CH₂)_(n)—, —CH₂—S—C(O)—(CH₂)_(n)—,    —(CH₂)_(n)—O—C(O)—CH₂—CH₂—, (CH₂)_(n)—NH—C(O)—CH₂—CH₂—, or    (CH₂)_(n)—S—C(O)—CH₂—CH₂—, wherein n is an integer from 1 to 7;-   B is O, S, S(O)(O), or NR⁵; and-   each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is independently    hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,    arylalkyl, substituted arylalkyl, cycloalkyl, substituted    cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,    heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted    heteroarylalkyl, acylalkyloxycarbonyl, acyloxyalkyloxycarbonyl,    acylalkyloxycarbonylamino, acyloxyalkyloxycarbonylamino, alkoxy,    alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonyllalkylamino,    alkylsulfinyl, alkylsulfonyl, alkylthio, amino, alkylamino,    arylalkylamino, dialkylamino, arylalkoxy, arylalkoxycarbonylalkoxy,    arylalkoxycarbonylalkylamino, aryloxycarbonyl,    aryloxycarbonylalkoxy, aryloxycarbonylalkylamino, carboxy,    carbamoyl, carbamate, carbonate, cyano, halo, heteroaryloxycarbonyl,    hydroxy, phosphate, phosphonate, sulfate, sulfonate, or sulfonamide,    wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ and A may optionally be    substituted with isotopes that include, but not limited to ²H    (deuterium), ³H (tritium), ¹³C, ³⁶Cl, ¹⁸F, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P,    and ³⁵S;    or a pharmaceutically acceptable salt, racemate or diastereomeric    mixtures thereof.

In another aspect, compounds of Formula (1a) are described:

wherein:

-   A is —(CH₂)_(n)—, —O—(CH₂)_(n)—, —S—(CH₂)_(n)—, —S(O)(O)—(CH₂)_(n)—,    —NH—(CH₂)_(n)—, —CH₂—O—(CH₂)_(n)—, —(CH₂)_(n)—O—CH₂—CH₂—,    —CH₂—S—(CH₂)_(n)—, —(CH₂)_(n)—S—CH₂—CH₂—, —CH₂—S(O)(O)—(CH₂)_(n)—,    —(CH₂)_(n)—S(O)(O)—CH₂—CH₂—, —O—C(O)—(CH₂)_(n)—, —S—C(O)—(CH₂)_(n)—,    —NH—C(O)—(CH₂)_(n)—, —CH₂—C(O)—O—(CH₂)_(n)—,    —CH₂—C(O)—NH—(CH₂)_(n)—, —CH₂—C(O)—S—(CH₂)_(n)—,    —(CH₂)_(n)—C(O)—O—CH₂—CH₂—, —(CH₂)_(n)—C(O)—NH—CH₂—CH₂—,    —(CH₂)_(n)—C(O)—S—CH₂—CH₂—, —CH₂—O—C(O)—(CH₂)_(n)—,    —CH₂—NH—C(O)—(CH₂)_(n)—, —CH₂—S—C(O)—(CH₂)_(n)—,    —(CH₂)_(n)—O—C(O)—CH₂—CH₂—, (CH₂)_(n)—NH—C(O)—CH₂—CH₂—, or    (CH₂)_(n)—S—C(O)—CH₂—CH₂—, wherein n is an integer from 1 to 7;-   B is O, S, S(O)(O), or NR⁵; and-   each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is independently    hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,    arylalkyl, substituted arylalkyl, cycloalkyl, substituted    cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,    heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted    heteroarylalkyl, acylalkyloxycarbonyl, acyloxyalkyloxycarbonyl,    acylalkyloxycarbonylamino, acyloxyalkyloxycarbonylamino, alkoxy,    alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonyllalkylamino,    alkylsulfinyl, alkylsulfonyl, alkylthio, amino, alkylamino,    arylalkylamino, dialkylamino, arylalkoxy, arylalkoxycarbonylalkoxy,    arylalkoxycarbonylalkylamino, aryloxycarbonyl,    aryloxycarbonylalkoxy, aryloxycarbonylalkylamino, carboxy,    carbamoyl, carbamate, carbonate, cyano, halo, heteroaryloxycarbonyl,    hydroxy, phosphate, phosphonate, sulfate, sulfonate, or sulfonamide,    wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ and A may optionally be    substituted with isotopes that include, but not limited to ²H    (deuterium), ³H (tritium), ¹³C, ³⁶Cl, ¹⁸F, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P,    and ³⁵S;    or a pharmaceutically acceptable salt, racemate or diastereomeric    mixtures thereof.

In another aspect of the invention, A is —(CH₂)_(n)—.

In another aspect of the invention, A is —O—(CH₂)_(n)—, —S—(CH₂)_(n)—,—CH₂—O—(CH₂)_(n)—, —(CH₂)_(n)—O—CH₂—CH₂—, —CH₂—S—(CH₂)_(n)—, or—(CH₂)_(n)—S—CH₂—CH₂—.

In another aspect of the invention, A is —NH—C(O)—(CH₂)_(n)—,—CH₂—NH—C(O)—(CH₂)_(n)—, —CH₂—C(O)—NH—(CH₂)_(n)— or—(CH₂)_(n)—C(O)—NH—CH₂—CH₂—.

In another aspect of the invention, B is O.

In another aspect of the invention, R⁴ is H.

In another aspect of the invention, each of R¹ and R² is independentlyH, halogen, haloalkyl or alkoxy.

The compounds of this invention described herein can have one or more ofthe following characteristics or properties:

-   -   (a) Compounds of the invention can have affinity for dopamine D₂        receptors;    -   (b) Compounds of the invention can have affinity for serotonin        5-HT_(1A) receptors;    -   (c) Compounds of the invention can have affinity for serotonin        5-HT_(2A) receptors;    -   (d) The primary metabolite(s), regardless of the        electrophysiological properties of the parent drug, has, or        have, negligible inhibitory activity at the HERG (human        ether-a-go-go related gene) potassium channel at the normal        therapeutic concentration of the parent drug in plasma (e.g. the        concentration of the metabolite must be at least five times        higher than the normal therapeutic concentration of the parent        compound before activity at the HERG potassium channel is        observed);    -   (e) Compounds of the invention, as well as the metabolites        thereof, do not cause, or have reduced incidence of metabolic        drug-drug interaction (DDI) when co-administered with other        drugs;    -   (f) Compounds of the invention, as well as metabolites thereof,        do not substantially elevate liver function test (LFT) values        when administered alone;    -   (g) Oral bioavailability of the compounds is consistent with        oral administration using standard pharmacological oral        formulations; however, the compounds, and compositions thereof,        can also be administered using any delivery system that produces        constant and controllable blood levels overt time.

In one aspect, the invention provides compounds having any two or moreof the above-identified characteristics or properties. In anotheraspect, the invention provides for compounds having at least any threeor more of the above-identified properties or characteristics.Preferably, the compounds of the invention have all sevencharacteristics or properties.

Additional modifications of the compounds disclosed herein can readilybe made by those skilled in the art. Thus, analogs and salts of theexemplified compounds are within the scope of the subject invention.With knowledge of the compounds of the subject invention skilledartisans can use known procedures to synthesize these compounds fromavailable substrates. As used in this application, the term “analogs”refers to compounds which are substantially the same as another compoundbut which may have been modified by, for example, adding additional sidegroups. The term “analogs” as used in this application also may refer tocompounds which are substantially the same as another compound but whichhave atomic or molecular substitution at certain locations in thecompound.

The subject invention further pertains to enantiomerically isolatedcompounds, and compositions comprising the compounds. The isolatedenantiomeric forms of the compounds of the invention are substantiallyfree from one another (i.e., in enantiomeric excess). In other words,the “R” forms of the compounds are substantially free from the “S” formsof the compounds and are, thus, in enantiomeric excess of the “S” forms.Conversely, “S” forms of the compounds are substantially free of “R”forms of the compounds and are, thus, in enantiomeric excess of the “R”forms. In one embodiment of the invention, the isolated enantiomericcompounds are at least about in 80% enantiomeric excess. Thus, forexample, the compounds are at least about 90% enantiomeric excess,preferably at least about 95% enantiomeric excess, more preferably atleast about 97% enantiomeric excess, or even more preferably, at least99% or greater than 99% enantiomeric excess.

SYNTHESIS OF THE COMPOUNDS OF THE INVENTION

The compounds of the invention can be obtained via the synthetic methodsillustrated in Schemes 1-2. Several methods have been described in theart for the synthesis of arylpiperazine derivatives. The startingmaterials and building blocks useful for preparing compounds of theinvention and intermediates thereof are commercially available or can beprepared by well-known synthetic methods (see e.g., Green et al.,“Protective Groups in Organic Chemistry,” (Wiley, 4th ed., 2006);Harrison et al “Compendium of Synthetic Organic Methods,” vols. 1-8(John Wiley and Sons, 1971-1996); “Beilstein Handbook of OrganicChemistry, Frankfurt, Germany; Feiser et al, “Reagents for OrganicSynthesis,” Volumes 1-45, Karger, 1991; March, Advanced OrganicChemistry,” Wiley Interscience, 4^(th) ed., 1991; Larock “ComprehensiveOrganic Transformations,” Wiley-VCH Publishers, 2^(nd) ed., 1999;Paquette, “Encyclopedia of Reagents for Organic Synthesis,” John Wileyand Sons, 1^(st) ed., 1995). Other methods for the synthesis ofarylpiperazine derivatives described herein are either described in theart or will be readily apparent to the skilled artisan in view of thereferences provided above and may be used to synthesize the compounds ofthe invention. Accordingly, the methods presented in the Schemes hereinare illustrative rather than comprehensive.

In one method arylpiperazine derivatives comprising Formula (1) wasprepared as described in Scheme1. The starting building block6-nitrobenzoxazinone 1 was purchased from the commercial sourceSigma-Aldrich. The compound 1 can also be synthesized from a method wellknown in the literature. The reduction of nitro moiety in compound 1using a reducing agent like potassium borohydride (KBH4) in presence ofa mild Lewis acid copper (1) chloride (CuCl) in a protic solvent such asmethanol gave 6-aminobenzoxazinone 2. The target benzoxazinone 4 wasprepared by coupling the amine 2 with a suitable carboxylic acid 3 understandard coupling conditions using dicyclohexylcarbodiimde (DCC) ascoupling agent in presence of a mild base 4-(N,N,-dimethylamino)pyridine(DMAP) in a polar aprotic solvent medium. The carboxylic acid 3 wasprepared by the alkylation of a suitable arylpiperazine with anappropriate bromocarboxylicacid ester followed by saponification. Thebenzoxazinone derivative 4 was converted into hydrochloride salt 5 bytreating with hydrogen chloride under standard conditions. Thebenzoxazinones 4 can also be converted into other form ofpharmaceutically acceptable salts such as methanesulfonic acid salts andlower aliphatic carboxylic acid salts using well known methods in thefield.

In another method, arylpiperazine derivatives comprising Formula (1)were prepared as described in Scheme 2. The starting building block4-methoxy-2-nitrophenol 6 was purchased from the commercial sourceSigma-Aldrich. The nitrophenol 6 was alkylated with ethylbromoacetate 7by heating in acetone in presence of a mild base potassium carbonate(K₂CO₃) to give the ester 8. The ester 8 was treated with aluminumchloride (AlCl₃) in anhydrous dichloromethane at reflux temperature toget the corresponding nitrophenol derivative 9. The compound 11 wasprepared by alkylating the nitrophenol 9 with 1,4-dibromobutane 10 underidentical reaction conditions described for preparing the compound 8(Scheme 2). The reaction of compound 11 with arylpiperazine 12 inpresence of N,N-diisopropylethylamine (DIEA) in acetonitrile atapproximately 60-70° C. for 8 to 16 h gave the compound 13. The compound13 when subjected to reduction conditions using iron (III) chloride inpresence of metallic iron in ethanol and acetic acid solvent mixture atreflux temperature afforded the corresponding benzoxazinone 14 which wasconverted into hydrochloride salt 15 by treating with hydrogen chlorideunder standard conditions. Other standard nitro group reductionconditions like hydrogenation in presence of catalyst palladium onactivated carbon (Pd/C) also gave corresponding cyclized product 14. Thebenzoxazinones 14 can also be converted into other form ofpharmaceutically acceptable salts such as methanesulfonic acid salts andlower aliphatic carboxylic acid salts using well known methods in thefield.

Therapeutic Uses of Compounds of Structural Formula (1)

The present invention relates to synthesis, compositions and methods ofusing arylpiperazine based compounds which are useful for treatingschizophrenia and related psychoses such as acute maniac, bipolardisorder, autistic disorder and depression. The present inventionprovides methods for synthesizing such arylpiperazine basedantipsychotic agents. The present invention also provides methods forusing arylpiperazine based antipsychotic agents and composition ofarylpiperazine based antipsychotic agents for treating schizophrenia andrelated psychoses such as acute maniac, bipolar disorder, autisticdisorder and depression.

In accordance with the invention, a compound and/or a compositioncontaining a compound of structural Formula (1) is administered to apatient, preferably a human, suffering from schizoprenia. Further, incertain embodiments, the compounds and/or compositions of the inventionare administered to a patient, preferably a human, as a treatment orpreventive measure against acute manic, bipolar disorder, autisticdisorder and depression.

Thus, those of skill in the art may readily assay and use the compoundsand/or compositions containing compound(s) of structural Formula (1) totreat a medical condition for which an antipsychotic is desired.

Therapeutic/Prophylactic Administration

The compounds, and/or compositions containing compounds(s), ofstructural Formula (1) can be advantageously used in human medicine. Aspreviously described in detail above, compounds and compositionscontaining compound(s) of structural Formula (1) are useful for thetreatment of schizophrenia and related psychoses such as acute manic,bipolar disorder, autistic disorder and depression.

When used to treat or prevent the above disease or disorders compoundsand/or compositions of the invention can be administered or appliedsingly, in combination with other agents. The compounds and/orcompositions of the invention can also be administered or appliedsingly, in combination with other pharmaceutically active agents,including other compounds and/or compositions of the invention.

The current invention provides methods of treatment and prophylaxis byadministration to a patient of a therapeutically effective amount of acomposition and/or compound of the invention. The patient may be ananimal, is more preferably a mammal, and most preferably a human.

The present compounds and/or compositions of the invention, whichcomprise one or more compounds and/or compositions of the invention arepreferably administered orally. The compounds and/or compositions of theinvention may also be administered by any other convenient route, forexample, by infusion or bolus injection, by absorption throughepithelial or mucocutaneous linings (e.g., oral mucosa, rectal andintestinal mucosa, etc.). Administration can be systemic or local.Various delivery systems are known, (e.g., encapsulation in liposomes,microparticles, microcapsules, capsules, etc.) that can be used toadminister a compound and/or composition of the invention. Methods ofadministration include, but are not limited to, intradermal,intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,epidural, oral, sublingual, intranasal, intracerebral, intravabinal,transdermal, rectally, by inhalation, or topically, particularly to theears, nose, eyes or skin.

In particularly, preferred embodiments, the compounds and/orcompositions of the invention can be delivered via sustained releasesystems, preferably oral sustained release systems. In one embodiment, apump may be used (see, Langer, supra; Sefton, 1987, CRC Crit. RefBiomed. Eng. 14:201; Saudek et al., 1989, N. Engl. J. Med. 321:574).

In another embodiment, polymeric materials can be used (see “MedicalApplications of Controlled Release,” Langer and Wise (eds.), Wiley, NewYork (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. MacromolChem. 23:61; see also Levy et al., 1985, Science 228:190; During et al.,1989, Ann. Neurol. 25:351; Howard et al, 1989, J. Neurosurg. 71:105). Ina preferred embodiment, polymeric materials are used for oral sustainedrelease delivery. Preferred polymers include sodiumcarboxymethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose and hydroxyethylcellulose (most preferred,hydroxypropylmethylcellulose). Other preferred cellulose ethers havebeen described in the art (Bamba et al., Int. J. Pharm., 1979, 2, 307).

In another embodiment, enteric-coated preparations can be used for oralsustained release administration. Preferred coating materials includepolymers with a pH-dependent solubility (i.e., pH-controlled release),polymers with a slow or pH-dependent rate of swelling, dissolution orerosion (i.e., time controlled release), polymers that are degraded byenzymes (i.e., enzyme controlled release) and polymers that form firmlayers that are destroyed by an increase in pressure (i.e.,pressure-controlled release).

In still another embodiment, osmotic delivery systems are used for oralsustained release administration (Verma et al., Drug Dev. Ind. Pharm.,2000, 26:695-708). In a preferred embodiment, OROS® osmotic deliverysystems are used for oral sustained release delivery devices (See forexample, Theeuwes et al., U.S. Pat. No. 3,845,770; and Theeuwes et al,U.S. Pat. No. 3,916,899).

In yet another embodiment, a controlled-release system can be placed inproximity of the target of the compounds and/or composition of theinvention, thus requiring only a fraction of the systemic dose (See,e.g., Goodson, in “Medical Applications of Controlled Release,” supra,vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussedin Langer, 1990, Science 249:1527-1533 may also be used.

The compounds, and/or compositions containing compound(s) of structuralFormula (1) of the invention may be cleaved either chemically and/orenzymatically. One or more enzymes present in the stomach, intestinallumen, intestinal tissue, blood, liver, brain or any other suitabletissue of a mammal may enzymatically cleave the compounds and/orcompositions of the invention.

Compositions of the Invention

In one aspect of the invention, pharmaceutical compositions are providedcomprising the compounds of the present disclosure.

The present composition contain a therapeutically effective amount ofone or more compounds of the invention, preferably in purified form,together with a suitable amount of a pharmaceutically acceptablevehicle, which so as to provide the form for proper administration to apatient. When administered to a patient, the compounds of the inventionand pharmaceutically acceptable vehicles are preferably sterile. Wateris preferred vehicle when the compound of the invention is administeredintravenously. Saline solutions and aqueous dextrose and glycerolsolutions can also be employed as liquid vehicles, particularly forinjectable solutions. Suitable pharmaceutical vehicles also includeexcipients such as starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,water, ethanol and the like. The present agents, or pH buffering agents.In addition, auxiliary, stabilizing, thickening, lubricating andcoloring agents may be used.

Pharmaceutical compositions comprising a compound of the invention maybe manufactured by means of conventional mixing, dissolving,granulating, dragee-making levigating, and emulsifying, encapsulating,entrapping or lyophilizing process. Pharmaceutical compositions may beformulated in conventional manner using one or more physiologicallyacceptable carriers, diluents, excipients or auxiliaries, whichfacilitate processing of compounds of the invention into preparationswhich can be used pharmaceutically. Proper formulation is dependent uponthe route of administration chosen.

The present compositions can take the form of solutions, suspensions,emulsion, tablets, pills, pellets, and capsules, capsules containingliquids, powders, sustained-release formulations, suppositories,emulsions, aerosols, sprays, suspensions, or any other form suitable foruse. In one embodiment, the pharmaceutically acceptable vehicle is acapsule (see e.g., Grosswald et al., U.S. Pat. No. 5,698,155). Otherexamples of suitable pharmaceutical vehicles have been described in theart (see Remington's Pharmaceutical Sciences, Philadelphia College ofPharmacy and Science, 17^(th) Edition, 1985). Preferred compositions ofthe invention are formulated for oral delivery, particularly for oralsustained release administration.

Compositions for oral delivery may be in the form of tablets, lozenges,aqueous or oily suspensions, granules, powders, emulsions, capsules,syrups or elixirs, for example. Orally administered compositions maycontain one or more optionally agents, for example, sweetening agentssuch as fructose, aspartame or saccharin; flavoring agents such aspeppermint, oil of wintergreen, or cherry coloring agents and preservingagents to provide a pharmaceutically palatable preparation. Moreover,where in tablet or pill form, the compositions may be coated to delaydisintegration and absorption in the gastrointestinal tract, therebyproviding a sustained action over an extended period of time.Selectively permeable membranes surrounding an osmotically activedriving compound are also suitable for orally administered compounds ofthe invention. In these later platforms, fluid from the environmentsurrounding the capsule is imbibed by the driving compound, which swellsto displace the agent or agent composition through an aperture. Thesedelivery platforms can provide an essentially zero order deliveryprofile as opposed to the spiked profiles of immediate releaseformulations. A time delay material such as glycerol monostearate orglycerol stearate may also be used. Oral compositions can includestandard vehicles such as mannitol, lactose, starch, magnesium stearate,sodium saccharine, cellulose, magnesium carbonate, etc. Such vehiclesare preferably of pharmaceutical grade.

For oral liquid preparations such as, for example, suspensions, elixirsand solutions, suitable carriers, excipients or diluents include water,saline, alkyleneglycols (e.g., propylene glycol), polyalkylene glycols(e.g., polyethylene glycol) oils, alcohols, slightly acidic buffersbetween pH 4 and pH 6 (e.g., acetate, citrate, ascorbate at betweenabout mM to about 50 mM) etc. Additionally, flavoring agents,preservatives, coloring agents, bile salts, acylcamitines and the likemay be added.

Compositions for administration via other routes may also becontemplated. For buccal administration, the compositions may take theform of tablets, lozenzes, etc. formulated in conventional manner.Liquid drug formulations suitable for use with nebulizers and liquidspray devices and EHD aerosol devices will typically include a compoundof the invention with a pharmaceutically acceptable vehicle. Preferably,the pharmaceutically acceptable vehicle is a liquid such as alcohol,water, polyethylene glycol or a perfluorocarbon. Optionally, anothermaterial may be added to alter the aerosol properties of the solution orsuspension of compounds of the invention. Preferably, this material isliquid such as alcohol, glycol, polyglycol or fatty acid. Other methodsof formulating liquid drug solutions or suspension suitable for use inaerosol devices are known to those of skill in the art (see, e.g.,Biesalski, U.S. Pat. No. 5,112,598; Biesalski, U.S. Pat. No. 5,556,611).A compound of the invention may also be formulated in rectal or vaginalcompositions such as suppositories or retention enemas, e.g., containingconventional suppository bases such as cocoa, butter or otherglycerides. In addition to the formulations described previously, acompound of the invention may also be formulated as depot preparation.Such long acting formulations may be administered by implantation (forexample, subcutaneously or intramuscularly) or by intramuscularinjection. Thus, for example, a compound of the invention may beformulated with suitable polymeric or hydrophobic materials (forexample, as an emulsion in an acceptable oil) or ion exchange resins, oras sparingly soluble derivatives, for example, as a sparingly solublesalt.

When a compound of the invention is acidic, it may be included in any ofthe above-described formulations as the free acid, a pharmaceuticallyacceptable salt, a solvate or hydrate. Pharmaceutically acceptable saltssubstantially retain the activity of the free acid, may be prepared byreaction with bases and tend to be more soluble in aqueous and otherprotic solvents than the corresponding free acid form.

Methods of Use and Doses

A compound of the invention, or compositions thereof, will generally beused in an amount effective to achieve the intended purpose. For use totreat schizophrenia and related psychoses such as acute manic, bipolardisorder, autistic disorder and depression. The compounds of Formula (1)and compositions containing a compound of Formula (1) are administeredor applied in a therapeutically effective amount.

The amount of a compound of the invention that will be effective in thetreatment of a particular disorder or condition disclosed herein willdepend on the nature of the disorder or condition, and can be determinedby standard clinical techniques known in the art as previouslydescribed. In addition, in vitro or in vivo assays may optionally beemployed to help identify optimal dosage ranges. The amount of acompound of the invention administered will, of course, is dependent on,among other factors, the subject being treated, and the weight of thesubject, the severity of the affliction, the manner of administrationand the judgment of the prescribing physician. For example, the dosagemay be delivered in a pharmaceutical composition by a singleadministration, by multiple applications or controlled release. In apreferred embodiment, the compounds of the invention are delivered byoral sustained release administration. Preferably, in this embodiment,the compounds of the invention are administered twice per day, and morepreferably, once per day. Dosing may be repeated intermittently, may beprovided alone or in combination with other drugs and may continue aslong as required for effective treatment of the disease state ordisorder.

The compounds and/or compositions containing compound(s), of structuralFormula (1) for the pharmacological treatment of schizophrenia andrelated psychoses such as acute maniac, bipolar disorder, autisticdisorder and depression may be administered in the range 0.1 mg to 500mg preferably 1 mg to 100 mg per day given in one or more doses and morepreferably 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 35 mg or 50 mg per day andmost preferably 10 mg.

The compounds of the invention are preferably assayed in vitro and invivo, for the desired therapeutic or prophylactic activity, prior to usein humans. The compounds of the invention may also be demonstrated to beeffective and safe using animal model systems.

Preferably, the therapeutically effective dose of a compound of theinvention described herein will provide therapeutic benefit withoutcausing substantial toxicity. Toxicity of compounds of the invention maybe determined using standard pharmaceutical procedures and may bereadily ascertained by the skilled artisan. The dose ratio between toxicand therapeutic effect is the therapeutic index. A compound of theinvention will preferably exhibit particularly high therapeutic indicesin treating disease and disorders. The dosage of a compound of theinventions described herein will preferably be within a range ofcirculating concentrations that include an effective dose with little orno toxicity.

In one aspect of the invention, methods of treating one of psychoses,schizophrenia, acute mania, bipolar disorder, autistic disorder ordepression are described, comprising administering to a patient in needthereof the compounds the present disclosure.

In another aspect of the invention, the method treats schizophrenia.

In another aspect of the invention, the method treats bipolar disorder.

In one aspect of the invention, compounds of the present disclosure usedto treat psychoses, schizophrenia, acute mania, bipolar disorder,autistic disorder or depression.

In another aspect of the invention, the use comprises the treatment ofschizophrenia.

In another aspect of the invention, the use comprises the treatment ofbipolar disorder.

In one aspect of the invention, compounds of the present disclosure areused in the manufacture of a medicament for use in the treatment ofpsychoses, schizophrenia, acute mania, bipolar disorder, autisticdisorder or depression treat psychoses, schizophrenia, acute mania,bipolar disorder, autistic disorder or depression.

In another aspect of the invention, the use is for the treatment ofschizophrenia.

In another aspect of the invention, the use is for the treatment ofbipolar disorder.

Combination Therapy

In certain embodiments of the present invention, the compounds of theinvention can be used in combination therapy with at least one othertherapeutic agent. The compound of the invention and the therapeuticagent can act additively or, more preferably, synergistically. In apreferred embodiment, composition comprising a compound of the inventionis administered concurrently with the administration of anothertherapeutic agent, which can be part of the same composition. In anotherembodiment, a composition comprising a compound of the invention isadministered prior or subsequent to administration of anothertherapeutic agent.

EXAMPLES

The invention is further defined by reference to the following examples,which describe in detail preparation of compounds and compositions ofthe invention and assays for using compounds and compositions of theinvention. It will be apparent to those skilled in the art that manymodifications, both to materials and methods, may be practiced withoutdeparting from the scope of the invention.

In the examples below, the following abbreviations have the followingmeanings. If an abbreviation is not defined, it has its generallyaccepted meaning.

-   Atm=Atmosphere-   CDI=1,1′-Carbonyldiimidazole-   DCM=dichloromethane-   DMAP=4-N,N-dimethylaminopyridine-   DMF=N,N-dimethylformamide-   g=gram-   h=hours-   L=liter-   LC/MS=liquid chromatography/mass spectroscopy-   M=molar-   mL=milliliter-   mmol=millimols-   nM=nanomolar-   gM=micromolar-   MTBE=methyl tert-butyl ether-   rt=room temperature-   TEA=triethylamine-   THF=tetrahydrofuran-   TFA=trifluoroacetic acid

Example 1

6-Amino-2H-benzo[b][1,4]oxazin-3(4H)-one (2) (Scheme 1). To a suspensionof 6-nitro-2H-1,4-benzoxazin-3(4H)-one 1 (0.5 g, 0.0026 mol) and CuCl(0.77 g, 0.0078 mol) in anhydrous methanol (25 mL), stirred at 25° C.was added potassium borohydride (0.98 g, 0.018 mol) in portions(exothermic with evolution of hydrogen gas). The reaction mixture wasstirred at 25° C. for 30 min. The black precipitate formed was filteredand washed with methanol. The combined filtrate and washings wasevaporated to give 6-amino-2H-benzo[b][1,4]oxazin-3(4H)-one which waspurified by silica gel column chromatography using ethyl acetate. Brownsolid (0.29 g, 67%). ¹H NMR (400 MHz, CDCl₃): δ 4.34 (s, 2H); 4.81 (s,2H); 6.09 (dd, J=2.8, 8.4 Hz, 1H); 6.14 (d, J=2.8 Hz, 1H); 6.59 (d,J=8.4 Hz, 1H); 10.44 (s, 1H).

Example 2

4-(4-(2-Methoxyphenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamide(4a) (Scheme 1). A mixture of 6-amino-2H-benzo[b][1,4]oxazin-3(4H)-one 2(0.08 g, 0.0005 mol), 4-(4-(substituted-phenyl)piperazin-1-yl)butanoicacid 3a (0.0005 mol), dicyclohexylcarbodiimide (0.1 g, 0.0005 mol),4-(dimethylamino)pyridine (0.006 g, 0.00005 mol) in 10 mLdichloromethane was stirred at room temperature for overnight. Theprogress of the reaction was monitored by thin layer chromatography(TLC). The reaction mixture was cooled; filtered to remove the ureaprecipitated, washed with saturated sodium bicarbonate solution, driedover sodium sulfate and evaporated under reduced pressure to give4-(4-(substituted-phenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamide4a which was purified by silica gel column chromatography using 0-10%gradient of ethyl acetate and methanol. The pure product 4a gavesatisfactory 1H NMR and/or Mass spectral data. White solid (0.06 g,29%). ¹H NMR (400 MHz, CDCl₃): δ 1.94-2.00 (m, 2H); 2.53-2.59 (m, 4H);2.70 (br s, 4H); 3.14 (br s, 4H); 3.87 (s, 3H); 4.55 (s, 2H); 6.63 (dd,J=2.4, 8.8 Hz, 1H); 6.84-6.88 (m, 2H); 6.93-6.95 (m, 2H); 6.99-7.04 (m,1H); 7.82 (d, J=2.4 Hz, 1H); 9.04 (br s, 1H); 9.12 (br s, 1H). MS (ESI):m/z=425.2 (M+H⁺).

Example 3

4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamide(4b) (Scheme 1). The compound 4b was synthesized using the protocoldescribed for the synthesis of compound 4a in Example 2 (Scheme 1).White solid (0.08 g, 34%). ¹H NMR (400 MHz, CDCl₃): δ 1.93-2.00 (m, 2H);2.50-2.57 (m, 4H); 2.68 (br s, 4H); 3.09 (br s, 4H); 4.50 (s, 2H); 6.63(dd, J=2.4, 8.8 Hz, 1H); 6.88 (d, J=8.8 Hz; 1H); 6.99-6.92 (m, 1H);7.13-7.20 (m, 2H); 7.71-7.72 (m, 1H); 8.46 (br s, 1H); 8.58 (br s, 1H).MS (ESI): m/z=463.2 (M⁺).

Example 4

4-(4-(2-Methoxyphenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamidehydrochloride (5a) (Scheme 1). To a solution of4-(4-(substituted-phenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamide4a in 5 mL dichloromethane was added 2 mL 2M HCl solution in diethylether, and then the solution was evaporated at 25° C. to give4-(4-(substituted-phenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamidehydrochloride 5a. The pure products 5a gave satisfactory 1H NMR and/orMass spectral data. White solid (60 mg). MS (ESI): m/z=425.2 (M−HCl).

Example 5

4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)butanamidehydrochloride (5b) (Scheme 1). The compound 5b was synthesized using theprotocol described for the synthesis of compound 5a in Example 4 (Scheme1). White solid (40 mg). MS (ESI): m/z=463.2 (M−HCl).

Example 6

Ethyl 2-(4-methoxy-2-nitrophenoxy)acetate (8) (Scheme 2). A mixture of4-methoxy-2-nitrophenol 6 (1.69 g, 0.01 mol), potassium carbonate (2.76g, 0.02 mol) and ethyl bromoacetate 7 (1.1 mL, 0.01 mol) in 20 mLanhydrous acetone was refluxed for overnight (12 h). The progress of thereaction was monitored by thin layer chromatography. The reactionmixture was evaporated, the residue was diluted with water and themixture was extracted with ethyl acetate. The organic layer was washedwith brine, dried over sodium sulfate and evaporated to give ethyl2-(4-methoxy-2-nitrophenoxy)acetate 8 which was purified by silica gelcolumn chromatography using 0-50% gradient of hexane and ethyl acetate.Yellow solid (2.18 g, 85%). ¹H NMR (400 MHz, CDCl₃): δ 1.28 (t, J=7.2Hz, 3H); 3.82 (s, 3H); 4.25 (q, J=7.2 Hz, 2H); 4.70 (s, 2H); 7.01 (d,J=9.2 Hz, 1H); 7.08 (dd, J=3.2, 9.2 Hz, 1H); 7.40 (d, J=2.8 Hz, 1H).

Example 7

Ethyl 2-(4-hydroxy-2-nitrophenoxy)acetate (9) (Scheme 2). To a solutionof ethyl 2-(4-methoxy-2-nitrophenoxy)acetate 8 (1.0 g, 0.004 mol) in 10mL dichloromethane cooled in an ice-bath was added aluminum chloride(1.6 g, 0.0133 mol) portion wise. The resulting mixture was graduallywarmed to room temperature and then refluxed for 4 h. The progress ofthe reaction was monitored by thin layer chromatography (TLC). Thereaction mixture was washed with saturated sodium bicarbonate solutionand dried over sodium sulfate to give ethyl2-(4-hydroxy-2-nitrophenoxy)acetate 9 which was purified by silica gelcolumn chromatography using a gradient of hexane and ethyl acetate.White solid (0.28 g, 37%). ¹H NMR (400 MHz, CDCl₃): δ 1.26 (t, J=6.8 Hz,3H); 4.27 (q, J=6.8 Hz, 2H); 4.71 (S, 2H); 6.32 (S, 1H); 6.90 (d, J=8.8Hz, 1H); 6.99 (dd, J=3.2 Hz; 8.8 Hz, 1H); 7.30 (d, J=2.8 Hz, 1H).

Example 8

Ethyl 2-(4-(4-bromobutoxy)-2-nitrophenoxy)acetate (11) (Scheme 2). To asolution of ethyl 2-(4-hydroxy-2-nitrophenoxy)acetate 9 (0.17 g, 0.0007mol) in 10 mL acetone was added potassium carbonate (0.39 g, 0.0028mol). The reaction mixture was stirred at room temperature for 10 min.Then 1,4-dibromobutane 10 (0.33 mL, 0.0028 mol) was added. The resultingmixture was heated at reflux for 12 h. The progress of the reaction wasmonitored by thin layer chromatography (TLC). Acetone was evaporated andthe residue was diluted with water, extracted with ethyl acetate anddried over sodium sulfate to give ethyl2-(4-(4-bromobutoxy)-2-nitrophenoxy)acetate 11 which was purified bysilica gel column chromatography using 0-20% gradient of hexane andethyl acetate. Yellow oil (0.52 g, 92%). ¹H NMR (400 MHz, CDCl₃): δ 1.26(t, J=6.8 Hz, 3H); 1.91-1.98 (m, 2H); 2.02-2.09 (m, 2H); 3.48 (t, J=6.8Hz, 2H); 3.99 (t, J=6.0 Hz, 2H); 4.26 (q, J=6.8 Hz, 2H); 4.70 (s, 2H);6.99-7.02 (m, 2H); 7.38 (d, J=3.2 Hz, 1H).

Example 9

Ethyl2-(4-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-2-nitrophenoxy)acetate13a (Scheme 2). A mixture of ethyl2-(4-(4-bromobutoxy)-2-nitrophenoxy)acetate 11 (0.0007 mol),1-(2-substituted-phenyl)piperazine hydrochloride 12 (0.16 g, 0.0007mol), N,N-diisopropylethylamine (0.36 mL, 0.0021 mol) in 10 mLacetonitrile was heated at 60° C. for 12 h. The progress of the reactionwas monitored by thin layer chromatography (TLC). The reaction mixturewas evaporated to remove the volatiles and the residue was diluted withwater, extracted with ethyl acetate, the organic extracts were washedwith sodium bicarbonate solution and dried over sodium sulfate to giveethyl2-(4-(4-(4-(substituted-phenyl)piperazin-1-yl)butoxy)-2-nitrophenoxy)acetate13a which was purified by silica gel column chromatography using agradient of hexane and ethyl acetate. The pure product 13a gavesatisfactory 1H NMR and/or Mass spectral data. Colorless oil (0.3 g,88%). ¹H NMR (400 MHz, CDCl₃): δ 1.26 (t, J=6.8 Hz, 3H); 1.70-1.72 (m,2H); 1.82-1.85 (m, 2H); 2.47 (t, J=6.4 Hz, 2H); 2.67 (br s, 4H); 3.10(br s, 4H); 3.86 (s, 3H); 3.98 (t, J=6.4 Hz, 2H); 4.24 (q, J=6.8 Hz,2H); 4.70 (s, 2H); 6.84-6.96-7.08 (m, 6H); 7.38 (d, J=2.8 Hz, 1H).

Example 10

Ethyl2-(4-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-nitrophenoxy)acetate13b (Scheme 2). The compound 13b was prepared using the protocoldescribed for the synthesis of compound 13a as described in Example 9(Scheme 2). Yellow oil (0.3 g, 81%). ¹H NMR (400 MHz, CDCl₃): δ 1.26 (t,J=6.8 Hz, 3H); 1.70-1.73 (m, 2H); 1.80-1.85 (m, 2H); 2.48 (t, J=6.4 Hz,2H); 2.65 (br s, 4H); 3.07 (br s, 4H); 3.99 (t, J=6.4 Hz, 2H); 4.26 (q,J=6.8 Hz, 2H); 4.70 (s, 2H); 6.94-7.08 (m, 3H); 7.13-7.16 (m, 2H); 7.39(d, J=3.2 Hz, 1H).

Example 11

6-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one(14a) (Scheme 2). Ethyl2-(4-(4-(4-(substituted-phenyl)piperazin-1-yl)butoxy)-2-nitrophenoxy)acetate13a (0.1 g, 0.0002 mol) was dissolved in a mixture of 10 mL ethanol and1.2 mL acetic acid in a 100 mL flask equipped with an efficientcondenser, and the stirred mixture brought to a gentle reflux. Ironpowder (0.084 g, 0.0015 mol) was added, followed immediately byiron(III) chloride hexahydrate (0.01 g, 0.000034 mol). The mixture wasrefluxed for a further 3 h, then cooled and filtered using a Buchnerfunnel, washed with ethanol. The combined filtrate and washings wereevaporated. To the residue was added ethyl acetate and water, and theaqueous layer was extracted twice with ethyl acetate. The combinedorganic layers were dried and concentrated to give6-(4-(4-(substituted-phenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one 14a which was purified by silica gel column chromatographyusing a gradient of hexane and ethyl acetate. The pure product 14a gavesatisfactory 1H NMR and/or Mass spectral data. Colorless oil (0.08 g,97%). ¹H NMR (400 MHz, CDCl₃): δ 1.70 (br s, 2H); 1.78 (br s, 2H); 2.47(br s, 2H); 2.67 (br s, 4H); 3.10 (br s, 4H); 3.86 (s, 3H); 3.91 (br s,2H); 4.55 (s, 2H); 6.38 (br s, 1H); 6-48-6.50 (m, 1H); 6.85-6.99 (m,5H); 9.12 (br s, 1H). MS (ESI): m/z=412.3 (M⁺+H).

Example 12

6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one(14b) (Scheme 2). The compound 14b was prepared using the protocoldescribed for the synthesis of compound 14a as described in Example 11(Scheme 2). Colorless oil (0.1 g, 42%). ¹H NMR (400 MHz, CDCl₃): δ 1.79(br s, 4H); 2.74 (br s, 2H); 2.96 (br s, 4H); 3.17 (br s, 4H); 3.91 (s,2H); 4.05 (s, 2H); 6.44 (s, 1H); 6.48 (dd, J=2.4 Hz; 8.8 Hz, 1H); 6.85(d, J=8.8 Hz, 1H); 6.96 (dd, J=2.0 Hz; 7.2 Hz, 1H); 7.12-7.19 (m, 2H);9.49 (s, 1H); 9.87 (br s, 1H). MS (ESI): m/z=450.2 (M⁺).

Example 13

6-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-onehydrochloride (15a) (Scheme 2). To a solution of6-(4-(4-(substituted-phenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one14a in 5 mL dichloromethane was added 2 mL 2M HCl solution in diethylether, and then the solution was evaporated at 25° C. to give6-(4-(4-(substituted-phenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-onehydrochloride 15a. The pure products 15a gave satisfactory 1H NMR and/orMass spectral data. White solid (0.08 g). MS (ESI): m/z=412.3 (M−HCl).

Example 14

6-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-onehydrochloride (15b) (Scheme 2). The compound 15b was prepared using theprotocol described for the synthesis of compound 15a as described inExample 13 (Scheme 2). White solid (0.28 g). MS (ESI): m/z=450.2(M−HCl).

In Vitro Pharmacology Results

The arylpiperazine derivatives comprising Formula (1) described in thisinvention were tested in the in vitro pharmacological assays to evaluatetheir activities for dopamine, D_(2S), serotonin, 5-HT_(1A) andserotonin, 5-HT_(2A) receptors. The in vitro assay protocols andliterature references are described herein.

Dopamine, D_(2S) (human recombinant) binding assay

Materials and Methods:

Receptor Source: Human recombinant expressed in CHO cells

Radioligand: [³H]Spiperone (20-60 Ci/mmol) Control Compound: Haloperidol

Incubation Conditions: The reactions were carried out in 50 mM TRIS-HCl(pH 7.4) containing 120 mM NaCl, 5 mM KCl, 5 mM MgCl₂, 1 mM EDTA for 60minutes at 25 C. The reaction was terminated by rapid vacuum filtrationonto glass fiber filters. Radioactivity trapped onto the filters wasdetermined and compared to control values in order to ascertain anyinteractions of test compounds with the cloned dopamine—D₂ short bindingsite (Literature Reference: Jarvis, K. R. et al. Journal of ReceptorResearch 1993, 13(1-4), 573-590; Gundlach, A. L. et al. Life Sciences1984, 35, 1981-1988.)

Serotonin, 5HT_(1A) (human recombinant) binding assay

Materials and Methods:

Receptor Source: Human recombinant expressed in HEK-293 cells

Radioligand: [³H]-8-OH-DPAT (221 Ci/mmol) Control Compound: 8-OH-DPAT

Incubation Conditions: The reactions were carried out in 50 mM TRIS-HCl(pH 7.4) containing 10 mM MgSO₄, 0.5 mM EDTA and 0.1% Ascorbic acid atroom temperature for 1 hour. The reaction was terminated by rapid vacuumfiltration onto glass fiber filters. Radioactivity trapped onto thefilters was determined and compared to control values in order toascertain any interactions of test compounds with the clonedserotonin-5HT_(1A) binding site (Literature Reference: Hoyer, D. et al.Eur. Journal Pharmacol. 1985, 118, 13-23; Schoeffter, P. and Hoyer, D.Naunyn-Schmiedeberg's Arch. Pharmac. 1989, 340, 135-138)

Serotonin, 5HT_(2A) (human) binding assay

Materials and Methods:

Receptor Source: Human Cortex Radioligand: [³H]-Ketanserin (60-90Ci/mmol) Control Compound: Ketanserin

Incubation Conditions: The reactions were carried out in 50 mM TRIS-HCl(pH 7.6) at room temperature for 90 minutes. The reaction was terminatedby rapid vacuum filtration onto glass fiber filters. Radioactivitytrapped onto the filters was determined and compared to control valuesin order to ascertain any interactions of test compounds with theserotonin-5HT_(2A) binding site (Literature Reference: Leysen, J. E. etal. Mol. Pharmacol. 1982, 21, 301-314; Martin, G. R. and Humphrey, P. P.A. Neuropharmacol. 1994, 33(3/4), 261-273.)

The radioligand binding assays for dopamine-D_(2S), serotonin-5HT_(1A)and serotonin-5HT_(2A) were carried out at six different concentrationsand the test concentrations were 0.5 nM, 1 nM, 10 nm, 100 nM, 300 nM and1000 nM.

The in vitro pharmacological activities of the selected compounds usingradioligand binding assays are reported in the following table.

Compound Assay IC50 Ki 15a (Example 13) D2S 0.98 nM 0.30 nM 15a (Example13) 5-HT1A 0.97 nM 0.65 nM 15a (Example 13) 5-HT2A 262 nM 118 nM 15b(Example 14) D2S 1.96 nM 0.61 nM 15b (Example 14) 5-HT1A 2.25 nM 1.50 nM15b (Example 14) 5-HT2A 130 nM 58.50 nM

While the invention has been particularly shown and described withreference to a preferred embodiment and various alternate embodiments,it will be understood by persons skilled in the relevant art thatvarious changes in form and details can be made therein withoutdeparting from the spirit and scope of the invention. All printedpatents and publications referred to in this application are herebyincorporated herein in their entirety by this reference.

1-13. (canceled)
 14. A compound having the formula below or apharmaceutically acceptable salt or isomer thereof:

wherein a) R¹=2-OMe and R²=H, or b) R¹=2-Cl and R²=3-Cl, and one or morehydrogens of the compound are optionally substituted with ²H(deuterium).
 15. The compound of claim 14, wherein R¹=2-Cl and R²=3-Cl.16. The compound of claim 14, wherein R¹=2-OMe and R²=H
 17. Apharmaceutical composition comprising the compound of claim 14 and apharmaceutically acceptable carrier, excipient or diluent.
 18. A methodof treating psychoses, schizophrenia, acute mania, bipolar disorder,autistic disorder or depression, the method comprising administering toa patient in need thereof the pharmaceutical formulation according toclaim
 17. 19. The method of claim 18, wherein said method treatsschizophrenia.
 20. The method of claim 18, wherein said method treatsbipolar disorder.